Nothing Special   »   [go: up one dir, main page]

CY1107096T1 - Μεθοδοι και φαρμακοτεχνικες μορφες ελεγχομενης απελευθερωσης παλιπεριδονης - Google Patents

Μεθοδοι και φαρμακοτεχνικες μορφες ελεγχομενης απελευθερωσης παλιπεριδονης

Info

Publication number
CY1107096T1
CY1107096T1 CY20071101601T CY071101601T CY1107096T1 CY 1107096 T1 CY1107096 T1 CY 1107096T1 CY 20071101601 T CY20071101601 T CY 20071101601T CY 071101601 T CY071101601 T CY 071101601T CY 1107096 T1 CY1107096 T1 CY 1107096T1
Authority
CY
Cyprus
Prior art keywords
paliperidone
methods
plasma concentration
detection
peak plasma
Prior art date
Application number
CY20071101601T
Other languages
English (en)
Inventor
Noymi V Yam
Iran Reyes
Nipun Davar
Atul D Ayer
Julie Lee
Original Assignee
Alza Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31191280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107096(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corporation filed Critical Alza Corporation
Publication of CY1107096T1 publication Critical patent/CY1107096T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Προβλέπονται φαρμακοτεχνικές μορφές και μέθοδοι για παροχή ανοδικού κατ’ ουσία ρυθμού αποδέσμευσης παλιπεριδόνης. Οι φαρμακοτεχνικές μορφές παρατεταμένης αποδέσμευσης όταν χορηγούνται εφάπαξ ημερησίως, προσφέρουν θεραπευτικά αποτελεσματικές, μέσης σταθερής κατάστασης συγκεντρώσεις παλιπεριδόνης στοπλάσμα. Το σχήμα των εφάπαξ ημερησίων δόσεων έχει ως αποτέλεσμα να προκύπτει μια μόνο μέγιστη συγκέντρωση παλιπεριδόνης στο πλάσμα κατά την περίοδο του 24ώρου. Επιπλέον, η μέγιστη συγκέντρωση της παλιπεριδόνης στο πλάσμα, επέρχεται σε χρόνο μετά τη χορήγηση της δόσης και εμφανίζεται σε μικρότερο βαθμό σε σχέση με τη μέγιστη συγκέντρωση της παλιπεριδόνης στο πλάσμα που επέρχεται μετά τη χορήγηση παλιπεριδόνης σε φαρμακοτεχνική μορφή άμεσης αποδέσμευσης.
CY20071101601T 2002-07-29 2007-12-18 Μεθοδοι και φαρμακοτεχνικες μορφες ελεγχομενης απελευθερωσης παλιπεριδονης CY1107096T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39959002P 2002-07-29 2002-07-29
US40600502P 2002-08-26 2002-08-26
EP03771910A EP1539115B1 (en) 2002-07-29 2003-07-28 Methods and dosage forms for controlled delivery of paliperidone

Publications (1)

Publication Number Publication Date
CY1107096T1 true CY1107096T1 (el) 2012-10-24

Family

ID=31191280

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101601T CY1107096T1 (el) 2002-07-29 2007-12-18 Μεθοδοι και φαρμακοτεχνικες μορφες ελεγχομενης απελευθερωσης παλιπεριδονης

Country Status (29)

Country Link
US (1) US20040092534A1 (el)
EP (1) EP1539115B1 (el)
JP (1) JP4500679B2 (el)
KR (1) KR100699516B1 (el)
CN (1) CN1684670A (el)
AR (1) AR040721A1 (el)
AT (1) ATE373472T1 (el)
AU (1) AU2003256844A1 (el)
BR (1) BR0313139A (el)
CA (1) CA2494234C (el)
CO (1) CO5580742A2 (el)
CY (1) CY1107096T1 (el)
DE (1) DE60316454T2 (el)
DK (1) DK1539115T3 (el)
ES (1) ES2293039T3 (el)
HK (1) HK1072559A1 (el)
HR (1) HRP20050077B1 (el)
IL (1) IL166489A (el)
MX (1) MXPA05001191A (el)
MY (1) MY137049A (el)
NO (1) NO324821B1 (el)
NZ (1) NZ570198A (el)
PE (1) PE20040132A1 (el)
PL (1) PL210119B1 (el)
PT (1) PT1539115E (el)
RU (1) RU2321391C2 (el)
TW (1) TWI363637B (el)
WO (1) WO2004010981A1 (el)
ZA (1) ZA200501641B (el)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
CA2575484A1 (en) * 2004-08-04 2006-02-16 Alza Corporation Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition
WO2006085856A1 (en) * 2005-02-04 2006-08-17 Alza Corporation Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20060189635A1 (en) * 2005-02-04 2006-08-24 Michelle Kramer Enhanced efficacy benzisoxazole derivative dosage forms and methods
EP1912622A2 (en) * 2005-08-04 2008-04-23 Alza Corporation Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties
US20070166381A1 (en) * 2006-01-06 2007-07-19 Iran Reyes Osmotic dosage form with controlled release and fast release aspects
EP3095447B1 (en) 2006-02-03 2021-11-24 OPKO Renal, LLC Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
US20070232624A1 (en) 2006-04-03 2007-10-04 Palumbo Joseph M Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients
WO2008008608A2 (en) 2006-06-21 2008-01-17 Proventiv Therapeutics, Llc Method of treating and preventing secondary hyperparathyroidism
US8524749B2 (en) * 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
PT2148661E (pt) 2007-04-25 2013-03-06 Proventiv Therapeutics Llc Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
WO2009025859A1 (en) * 2007-08-21 2009-02-26 Teva Pharmaceutical Industries Ltd. Paliperidone sustained release formulation
JP2010540465A (ja) 2007-09-25 2010-12-24 テバ ファーマシューティカル インダストリーズ リミティド 安定なイマチニブ組成物
MY204500A (en) * 2007-12-19 2024-08-30 Janssen Pharmaceutica Nv Dosing regimen associated with long acting injectable paliperidone esters
EP2280967A2 (en) * 2008-03-27 2011-02-09 Actavis Group PTC EHF Highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity
WO2010009900A1 (en) * 2008-07-25 2010-01-28 Krka, D.D. Novo Mesto Paliperidone composition comprising solid matrix particles
EP2161019A1 (en) 2008-09-05 2010-03-10 KRKA, D.D., Novo Mesto Prolonged release multiparticulate pharmaceutical composition comprising paliperidone
WO2010044097A2 (en) 2008-09-15 2010-04-22 Intas Pharmaceuticals Limited Novel dosage form of paliperidone and process for preparing the same
WO2010039722A1 (en) * 2008-09-30 2010-04-08 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of risperidone and methods of use thereof
WO2011018246A2 (en) 2009-08-13 2011-02-17 Synthon B.V. Controlled release paliperidone composition
US20110052687A1 (en) * 2009-08-26 2011-03-03 Glenmark Generics Ltd Extended release pharmaceutical composition of paliperidone
AU2010308021A1 (en) * 2009-10-16 2012-05-17 Ranbaxy Laboratories Limited Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
EP2547206B1 (en) * 2010-03-15 2016-05-11 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
PT2552484T (pt) 2010-03-29 2020-04-03 Opko Ireland Global Holdings Ltd Métodos e composições para redução dos níveis de parafróides
MX339805B (es) 2010-04-22 2016-06-10 Intra Cellular Therapies Inc Compuestos organicos.
US20120201886A1 (en) 2010-07-30 2012-08-09 Micro Labs Limited Coated Extended Release Pharmaceutical Compositions Containing Paliperidone
CN102058517A (zh) * 2010-12-31 2011-05-18 泰州万全医药科技有限公司 一种帕潘立酮缓释剂及其制备方法
US20130034605A1 (en) 2011-08-01 2013-02-07 Micro Labs Limited Extended release pharmaceutical compositions containing paliperidone
CN102274164B (zh) * 2011-08-22 2014-07-02 长春健欣生物医药科技开发有限公司 帕潘立酮及帕潘立酮衍生物的注射用缓释凝胶剂
CA2870303A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Organic compounds
WO2014102741A2 (en) * 2012-12-28 2014-07-03 University Of The Witwatersrand, Johannesburg Pharmaceutical dosage form
HUE053159T2 (hu) 2013-03-15 2021-06-28 Intra Cellular Therapies Inc Szerves vegyületek
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CN103271889B (zh) * 2013-05-23 2015-10-28 沈阳药科大学 帕利哌酮新型递增释放渗透泵制剂及其制备方法
CN103385857A (zh) * 2013-06-29 2013-11-13 北京万全德众医药生物技术有限公司 帕利哌酮的药物组合物
WO2015001488A1 (en) 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Extended-release tablets of paliperidone and processes of preparation thereof
CN105939712A (zh) 2013-12-03 2016-09-14 细胞内治疗公司 新方法
JP2017509677A (ja) 2014-04-04 2017-04-06 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
KR20170012210A (ko) 2014-04-04 2017-02-02 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
US20160000654A1 (en) * 2014-07-07 2016-01-07 Cadila Healthcare Limited Method for determining formulation orientation of asymmetric multi-layered osmotic tablets
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CN104257622B (zh) * 2014-10-01 2020-02-07 浙江华海药业股份有限公司 一种帕利哌酮控释片及其制备方法
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
GR1008842B (el) 2015-08-06 2016-09-05 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου
CN105147629B (zh) * 2015-09-24 2017-08-25 吉林大学 一种异丁利酮片剂及制备方法
PT3407888T (pt) 2016-01-26 2021-03-19 Intra Cellular Therapies Inc Compostos de piridopirroloquinoxalina, suas composições e utilizações
WO2017165843A1 (en) 2016-03-25 2017-09-28 Intra-Cellular Therapies, Inc. Organic compounds
BR112018069727A2 (pt) 2016-03-28 2019-02-05 Opko Ireland Global Holdings Ltd métodos de tratamento com vitamina d
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NEW COMPOSITIONS AND METHODS
WO2017174096A1 (en) 2016-04-05 2017-10-12 Pharmathen S.A. Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
EP3544593A4 (en) * 2016-11-23 2020-11-25 Children's Hospital Medical Center PALIPERIDONE FOR THE TREATMENT OF DRUG REFRACTORY IRRITABILITY AND AUTISTIC SPECTRUM DISORDER
CN106727392A (zh) * 2016-12-15 2017-05-31 上海奕利制药有限公司 一种帕利哌酮缓释片剂及其制备方法
US10906906B2 (en) 2016-12-29 2021-02-02 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
RU2022103663A (ru) 2017-03-24 2022-04-07 Интра-Селлулар Терапиз, Инк. Новые композиции и способы
IL272252B2 (en) 2017-07-26 2024-03-01 Intra Cellular Therapies Inc Transformed histories of gamma-carbolines fused with heterocyclics, pharmaceutical preparations containing them and their use for treatment
WO2019023062A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
US20210009592A1 (en) 2018-03-23 2021-01-14 Intra-Cellular Therapies, Inc. Organic compounds
AU2019240226A1 (en) 2018-03-23 2020-10-22 Intra-Cellular Therapies, Inc. Organic compounds
CA3102948A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
WO2020047407A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
CA3108558A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
JP2022539821A (ja) 2019-07-07 2022-09-13 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
KR102285510B1 (ko) 2019-10-29 2021-08-04 강동국 양액 농도조절용 캡슐 및 그 용도
CN113616610B (zh) * 2021-07-30 2023-05-12 石药集团欧意药业有限公司 一种帕利哌酮缓释片及其制备方法
WO2023220251A2 (en) * 2022-05-12 2023-11-16 Celanese Eva Performance Polymers Llc Implantable medical device for the delivery of an antipsychotic
WO2024145659A1 (en) 2022-12-30 2024-07-04 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656092A (en) * 1985-10-15 1987-04-07 R. P. Scherer Corporation Target shooting capsules
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
PT1033128E (pt) * 1993-09-28 2008-08-08 Scherer Gmbh R P Fabrico de cápsulas de gelatina mole
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
ES2194210T3 (es) * 1996-08-16 2003-11-16 Alza Corp Forma de dosificacion para suministrar una dosis ascendente de farmaco.
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
NZ508567A (en) * 1998-06-03 2004-02-27 Alza Corp Methods and devices for providing prolonged drug therapy
US6706282B1 (en) * 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
EP1126853B1 (en) * 1998-11-02 2006-04-19 ALZA Corporation Controlled delivery of antidepressants
EP1140012B1 (en) * 1998-12-17 2004-03-03 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
KR20060097068A (ko) * 1999-03-31 2006-09-13 얀센 파마슈티카 엔.브이. 방출 조절형 제제중의 프리젤라틴화 전분
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6375981B1 (en) * 2000-06-01 2002-04-23 A. E. Staley Manufacturing Co. Modified starch as a replacement for gelatin in soft gel films and capsules
US6530962B1 (en) * 2001-08-31 2003-03-11 R.P. Scherer Technologies, Inc. Emulsion of water soluble dyes in a lipophilic carrier

Also Published As

Publication number Publication date
DE60316454D1 (de) 2007-10-31
TW200418524A (en) 2004-10-01
RU2321391C2 (ru) 2008-04-10
MY137049A (en) 2008-12-31
HRP20050077A2 (en) 2005-12-31
NZ570198A (en) 2010-01-29
NO324821B1 (no) 2007-12-10
CO5580742A2 (es) 2005-11-30
PT1539115E (pt) 2008-01-14
AR040721A1 (es) 2005-04-20
PE20040132A1 (es) 2004-03-06
KR20050044895A (ko) 2005-05-13
IL166489A0 (en) 2006-01-15
JP4500679B2 (ja) 2010-07-14
TWI363637B (en) 2012-05-11
IL166489A (en) 2014-01-30
PL376258A1 (en) 2005-12-27
DK1539115T3 (da) 2008-01-28
US20040092534A1 (en) 2004-05-13
CN1684670A (zh) 2005-10-19
EP1539115B1 (en) 2007-09-19
BR0313139A (pt) 2005-07-05
DE60316454T2 (de) 2008-06-26
KR100699516B1 (ko) 2007-03-26
RU2005102105A (ru) 2005-08-10
EP1539115A1 (en) 2005-06-15
ES2293039T3 (es) 2008-03-16
MXPA05001191A (es) 2005-09-12
WO2004010981A1 (en) 2004-02-05
HK1072559A1 (en) 2005-09-02
JP2005535682A (ja) 2005-11-24
HRP20050077B1 (hr) 2013-11-22
ZA200501641B (en) 2005-08-31
AU2003256844A1 (en) 2004-02-16
PL210119B1 (pl) 2011-12-30
CA2494234A1 (en) 2004-02-05
CA2494234C (en) 2009-10-27
NO20050956L (no) 2005-04-27
ATE373472T1 (de) 2007-10-15

Similar Documents

Publication Publication Date Title
CY1107096T1 (el) Μεθοδοι και φαρμακοτεχνικες μορφες ελεγχομενης απελευθερωσης παλιπεριδονης
BR0309620A (pt) Métodos e formas de dosagem para liberação controlada de oxicodona
DK1708686T3 (da) Generelt lineær effervescent oral fentanyldoseringsform og fremgangsmåder til indgivelse
UY30537A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
ES2153338T1 (es) Dosificacion mejorada de dosis multiples de medicamentos.
IS7142A (is) Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
MX2009013574A (es) Formas de dosificacion solidas o semisolidas de liberacion modificada.
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
EP1708685A4 (en) GALENIC FORMS OF EFFERVESCENT ORAL OPIATES AND METHODS OF ADMINISTERING OPIATES
NO20051854L (no) Vedvarende frigivelse opioidformuleringer og fremgangsmater for anvendelse.
CY1112811T1 (el) Απο το στοματος μορφη δοσολογιας που περιεχει αναστολεα ρdε 4 ως δραστικο συστατικο και πολυβινυλοπυρρολιδονη ως εκδοχο
CY1106137T1 (el) Φαρμακευτικη συνθεση πepιλαμβανουσα λουμιρακοξιμπη
NO20073403L (no) Anvendelse av atazanavir til forbedring av farmakokinetikken til legemidler metabolisert av UGT1A1
ATE541562T1 (de) Ibuprofen-suspension
DE60030283D1 (de) Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
CY1110184T1 (el) Φαρμακευτικη συνθεση για μαλακες καψουλες για χορηγηση απο το στομα η οποια περιεχει βινορελβινη και μεθοδος θεραπειας
EA200300110A1 (ru) Композиция элетриптана в виде частиц
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
WO2005010022A3 (en) Agonist polypeptide of receptor for zot and zonulin
WO2003020214A3 (en) Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
CO5550418A2 (es) Formulaciones antihistaminicas para formas de dosificacion de capsula blanda
UY28457A1 (es) Nueva composición